SAB Biotherapeutics (NASDAQ:SABS) Coverage Initiated at Oppenheimer

Oppenheimer started coverage on shares of SAB Biotherapeutics (NASDAQ:SABS) in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage set an “outperform” rating and a $12.00 price target on the stock. Oppenheimer’s target price indicates a potential upside of 376.85% from the company’s previous close.

Other analysts also recently issued reports about the stock. Brookline Capital Management began coverage on shares of SAB Biotherapeutics in a report on Friday, June 7th. They set a “buy” rating and a $8.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of SAB Biotherapeutics in a research note on Monday, August 12th. Finally, Chardan Capital restated a “buy” rating and issued a $25.00 price target on shares of SAB Biotherapeutics in a research note on Monday, August 12th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $12.75.

SAB Biotherapeutics Price Performance

NASDAQ SABS opened at $2.52 on Wednesday. The company has a fifty day moving average of $2.76 and a 200 day moving average of $3.72. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.65 and a current ratio of 5.65. SAB Biotherapeutics has a 1 year low of $2.16 and a 1 year high of $10.50.

SAB Biotherapeutics (NASDAQ:SABS) last posted its earnings results on Thursday, August 8th. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($1.13) by $0.34. SAB Biotherapeutics had a negative return on equity of 109.90% and a negative net margin of 1,531.26%. The firm had revenue of $0.26 million for the quarter. On average, research analysts anticipate that SAB Biotherapeutics will post -4.08 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SAB Biotherapeutics

Hedge funds have recently made changes to their positions in the company. RTW Investments LP purchased a new stake in shares of SAB Biotherapeutics during the fourth quarter worth approximately $6,310,000. BVF Inc. IL acquired a new stake in SAB Biotherapeutics during the 4th quarter worth $6,310,000. Commodore Capital LP purchased a new stake in shares of SAB Biotherapeutics during the fourth quarter worth $1,259,000. Finally, First PREMIER Bank purchased a new position in shares of SAB Biotherapeutics in the second quarter worth about $60,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.